SHAPING THE FUTURE OF LEFT ATRIAL APPENDAGE CLOSURE

Rethinking LAA Closure Around Anatomy

Parasol MedTech is developing an integrated catheter-and-gel system designed to adapt to the unique anatomy of the left atrial appendage—with the goal of eliminating the need for a permanent metal implant.

THE CLINICAL CHALLENGE

Every Appendage Is Different

No two left atrial appendages are the same. Each has its own shape, size, depth, lobes, and internal geometry. Yet today’s closure technologies rely on permanent metallic implants with predetermined shapes and sizes.

For complex appendages, fitting a fixed mechanical structure to highly variable anatomy can create challenges with device selection, positioning, sealing, and fixation. And despite advances in LAA closure, residual leak, device-related thrombus, stroke, and bleeding remain important clinical concerns.

Variable Anatomy

Every LAA presents a unique three-dimensional geometry.

Challenging Fit

Traditional devices rely on predetermined shapes and sizes with permanent mechanical fixation.

HOW IT WORKS

Designed for Control; Built Around Anatomy

Parasol’s investigational platform combines temporary mechanical control with targeted gel delivery in a single integrated catheter system—designed to enable precise, anatomy-driven LAA closure.

PHYSICIAN-LED INNOVATION

Born From
Procedural Experience

After performing more than 1,000 left atrial appendage closure procedures, Dr. Atman Shah recognized a fundamental limitation of existing technology: fixed mechanical implants must fit highly variable anatomy.

Parasol was born from a different idea—an integrated catheter-and-gel platform designed to adapt to each patient’s unique anatomy.

Atman P. Shah, MD, FSCAI, FACC

Founder & Chief Medical Officer

EXECUTIVE LEADERSHIP

Experienced Leadership; Informed by Clinical Expertise

Atman P. Shah, MD, FSCAI, FACC

Founder & Chief Medical Officer

Interventional Cardiologist & Cardiac Cath Lab Director
UChicago Medicine
Performed more than 1,000 left atrial appendage closure procedures
Recognized clinical leader with extensive experience in physician proctoring, procedural training, and faculty roles at leading cardiovascular conferences.

Evan Singer

Chief Executive Officer

Company builder in highly regulated industries
Led new product commercialization and professional marketing supporting FDA 510(k) clearance for a new Class II medical device at Align Technology.
As CEO of SmartBiz, built one of the nation’s leading fintechs and led the company’s acquisition of a nationally chartered bank, securing Fed and OCC regulatory approval.

CLINICAL & STRATEGIC ADVISORS

Dhanunjaya (DJ) Lakkireddy

MD, MBA, FHRS

Executive Medical Director
Kansas City Heart Rhythm Institute
Professor of Medicine — University of Missouri
President-Elect — Heart Rhythm Society (HRS)

Devi G. Nair

MD, FACC, FHRS

Chief of Cardiac Electrophysiology & Research
St. Bernards Medical Center & White River Medical Center
CEO — Arrhythmia Research Group
Clinical Adjunct Professor — UAMS

Shephal K. Doshi

MD, FACC

Cardiac Electrophysiologist
Pacific Heart Institute

Mark D. Metzl

MD

Cardiac Electrophysiologist
Endeavor Health

Steven A. Gould

MD

Senior Advisor
Polsky Center for Entrepreneurship and Innovation
The University of Chicago

Jennifer Fried

MBA

Co-Founder & CEO
Flow Medical

MEDIA & ANNOUNCEMENTS

Latest From Parasol

ACC Among Investors Raising $2.75M for New LAAO Tech

ACC Among Investors Raising $2.75M for New LAAO Tech

Cardiovascular Business reports on Parasol Med Tech’s $2.75 million pre-seed funding round, backed by prominent healthcare investors, and its investigational catheter-and-gel approach to left atrial appendage closure.

Founded by Chicago Cardiologist, Parasol Secures $2.75M for Novel Medical Device to Improve Stroke Prevention

Founded by Chicago Cardiologist, Parasol Secures $2.75M for Novel Medical Device to Improve Stroke Prevention

The University of Chicago’s Polsky Center highlights Parasol Med Tech’s $2.75 million funding round, its origins in physician-led innovation, and the development of a novel approach to left atrial appendage closure.

Parasol Med Tech Secures $2.75M to Improve Stroke Prevention in Atrial Fibrillation

Parasol Med Tech Secures $2.75M to Improve Stroke Prevention in Atrial Fibrillation

Parasol Med Tech has closed an oversubscribed $2.75 million pre-seed funding round, with participation from Harper Court Ventures, UCM Ventures, and Cardiovascular Innovation Ventures. The funding will support continued development and testing of its investigational left atrial appendage closure platform.

CONNECT WITH PARASOL

Connect With Our Team

Connect with the Parasol Med Tech team to learn more about our investigational left atrial appendage closure platform and development efforts.


    Please do not submit personal medical information.